Ginkgo BioWorks Inc.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Ginkgo BioWorks Inc. - overview
Established
2008
Location
Boston, MA, US
Primary Industry
Biotechnology
About
Founded in 2008 and based in Massachusetts, US, Ginkgo BioWorks, Inc. develops and engineers microorganisms for multiple industries, such as food, cosmetics, farming, and pharmaceuticals. The company was founded by Austin Che, Barry Canton, Jason Kelly, Reshma Shetty, and Tom Knight. In May 2020, Ginkgo BioWorks, Inc.
raised USD 70 million in series F funding from new investor Illumina, Inc. and in May 2021, Soaring Eagle Acquisition Corp. , a special purpose acquisition company, agreed to acquire Ginkgo BioWorks, Inc. As of April 2026, the company is led by its CEO Jason Kelly.
The company operates a software platform that uses advanced robotic automation, data analytics, and genetic engineering to program and produce living cells like bacteria with industrial applications ranging from cheesemaking to medicine. Ginkgo Bioworks designs, engineers, develops, tests, and licenses microorganisms that can be used by other companies as microbial products for flavors, sweeteners, cosmetic ingredients, crop treatments, and pharmaceuticals. After the acquisition by Soaring Eagle Acquisition Corp. , the company plans to become a publicly listed company.
In 2021, Ginkgo expects to generate USD 150 million in revenue, which is approximately 96% growth compared to 2020.
Current Investors
Allen & Company, Cascade Investment, Viking Global Investors
Primary Industry
Biotechnology
Sub Industries
Bioinformatics, Biopharmaceuticals, Molecular Science, Genetics & Gene Therapy, Medical Software
Website
www.ginkgobioworks.com
Verticals
HealthTech
Company Stage
Mature
Total Amount Raised
Subscriber access only
Ginkgo BioWorks Inc. - timeline of key events
Ginkgo BioWorks Inc. - financials
| Fiscal Year Ended | Dec 31, 2019 | Dec 31, 2020 | Dec 31, 2021 | Dec 31, 2022 | Dec 31, 2023 | Dec 31, 2024 | Dec 31, 2025 |
|---|---|---|---|---|---|---|---|
| Revenue (USD) | 54,184,000 | 76,657,000 | 313,837,000 | 477,706,000 | - | - | - |
| % Revenue Growth (YoY) | - | 41.5% | 309.4% | 52.2% | - | - | - |
| EBITDA (USD) | (60,843,000) | (123,163,000) | (1,799,391,000) | (2,164,529,000) | - | - | - |
| Operating Income (USD) | (71,598,000) | (137,027,000) | (1,828,467,000) | (2,208,952,000) | - | - | - |
| Operating Margin | (132.1%) | (178.8%) | (582.6%) | (462.4%) | - | - | - |
| % EBITDA Margin | (112.3%) | (160.7%) | (573.4%) | (453.1%) | - | - | - |
| NET Income (USD) | (119,857,000) | (126,723,000) | (1,836,642,000) | (2,106,372,000) | - | - | - |
| % Net Margin | (221.2%) | (165.3%) | (585.2%) | (440.9%) | - | - | - |
Ginkgo BioWorks Inc. - deals
| Deals Type | Deal Status | Target (s) | Deal Date | Investor(s) | Seller(s) | Deal size (Mn) | Enterprise value (Mn) | Post-money valuation (Mn) | EBITDA multiple (x) | Revenue multiple (x) | Lead partner (s) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Corporate Carve Out | Completed | Perimeter Systems | - |
Displaying 1 - 1 of 1
Ginkgo BioWorks Inc. - employee data
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.